Restore their
psyches, protect
the Nation

"Ibogaine is a psychoactive indole alkaloid which is extracted from the Tabernanthe iboga rainforest shrub and has been used for centuries in Central Africa for initiatory rituals. Ibogaine was used in France for over 30 years as an anti-depressant and a stimulant until the mid-1960s. Ibogaine treatment is reported to alleviate a spectrum of mood and anxiety symptoms and is associated with self-reported improvements in cognitive functioning in individuals with substance use disorders. During treatment, ibogaine allows the evocation and reprocessing of traumatic memories and occasions therapeutic and meaningful visions of spiritual and autobiographical content which are of central relevance in addressing PTSD-related psychological content.'

"5-MeO-DMT is a psychedelic tryptamine found in plant species and notably in the venomous secretions of the Sonoran Desert/Colorado River toad. In observational studies, 5-MeO-DMT demonstrates therapeutic potential across a variety of psychiatric symptoms that correspond with common sequelae in Veteran populations. For example, in individuals who received vaporized 5-MeO-DMT in a group naturalistic setting, approximately 80% of those who reported a diagnosis of depression (n = 149) or anxiety (n = 173) endorsed improvements in these conditions following 5-MeO-DMT use. In an epidemiological survey of 515 individuals, participants who endorsed having psychiatric diagnoses indicated that their symptoms improved following 5-MeO-DMT use, including PTSD (79%)49 and depression (77%), and anxiety (69%)."

"Several small studies suggest the drugs can be safely administered and might have benefits for people with intractable depression and other psychological problems, such as post-traumatic stress disorder (PTSD). One clinical trial involving MDMA has recently ended, with results expected to be published soon. Regulators will then be considering whether to make the treatment available with a prescription.

Psychedelic-assisted psychotherapy could provide needed options for debilitating mental-health disorders including PTSD, major depressive disorder, alcohol-use disorder, anorexia nervosa and more that kill thousands every year in the United States, and cost billions worldwide in lost productivity."

"On March 5, 2019, the Food and Drug Administration (FDA) approved the first new medication for major depression in decades. The drug is a nasal spray called esketamine, derived from ketamine—an anesthetic that has made waves for its surprising antidepressant effect."

We are launching an art fundraiser in Washington DC in November of this year, fill out this form to stay in the loop and learn how to contribute.